A major obstacle for the discovery of psychoactive drugs is the inability to predict how small molecules will alter complex behaviors. We report the development and application of a high-throughput, quantitative screen for drugs that alter the behavior of larval zebrafish. We found that the multidimensional nature of observed phenotypes enabled the hierarchical clustering of molecules according to shared behaviors. Behavioral profiling revealed conserved functions of psychotropic molecules and predicted the mechanisms of action of poorly characterized compounds. In addition, behavioral profiling implicated new factors such as ether-a-go-go-related gene (ERG) potassium channels and immunomodulators in the control of rest and locomotor activity. These results demonstrate the power of high-throughput behavioral profiling in zebrafish to discover and characterize psychotropic drugs and to dissect the pharmacology of complex behaviors.
A major obstacle for the discovery of psychoactive drugs is the inability to predict how small molecules will alter complex behaviors. We report the development and application of a high-throughput, quantitative screen for drugs that alter the behavior of larval zebrafish. We found that the multidimensional nature of observed phenotypes enabled the hierarchical clustering of molecules according to shared behaviors. Behavioral profiling revealed conserved functions of psychotropic molecules and predicted the mechanisms of action of poorly characterized compounds. In addition, behavioral profiling implicated new factors such as ether-a-go-go-related gene (ERG) potassium channels and immunomodulators in the control of rest and locomotor activity. These results demonstrate the power of high-throughput behavioral profiling in zebrafish to discover and characterize psychotropic drugs and to dissect the pharmacology of complex behaviors. M ost current drug discovery efforts focus on simple in vitro screening assays. Although such screens can be successful, they cannot recreate the complex network interactions of whole organisms. These limitations are particularly acute for psychotropic drugs because brain activity cannot be modeled in vitro (1) (2) (3) . Motivated by recent small-molecule screens that probed zebrafish developmental processes (4) (5) (6) (7) , we developed a whole organism, highthroughput screen for small molecules that alter larval zebrafish locomotor behavior. We used an automated rest/wake behavioral assay (3, 8) to monitor the activity of larvae exposed to small molecules at 10 to 30 mM for 3 days (Fig. 1A ) (3) . Multiple behavioral parameters were measured, including the number and duration of rest bouts, rest latency, and waking activity (i.e., activity not including time spent at rest) ( Fig. 1B ) (3) . We screened 5648 compounds representing 3968 unique structures and 1680 duplicates and recorded more than 60,000 behavioral profiles. Of these, 547 compounds representing 463 unique structures significantly altered behavior relative to controls, according to a stringent statistical cutoff (3) .
Because the alterations in behavior were multidimensional and quantitative, we assigned a behavioral fingerprint to each compound and applied clustering algorithms to organize molecules according to their fingerprints (Fig. 2A and figs. S1 to S3) . This analysis organized the data set broadly into arousing and sedating compounds and identified multiple clusters corresponding to specific phenotypes (Fig. 2, B to F; Fig. 3, A to C; Fig. 4, B and C; and figs. S1 to S4) . Clustering allowed us to address three questions: (i) Do structural, functional, and behavioral profiles overlap? (ii) Does the data set predict links between known and unknown small molecules and their mechanisms of action? (iii) Does the data set identify unexpected candidate pathways that regulate rest/wake states?
Cluster analysis revealed several lines of evidence that molecules with correlated behavioral phenotypes often shared annotated targets or therapeutic indications (Fig. 2 , B to F, and figs. S1 to S4). First, drug pairs were more likely to be correlated if the compounds shared at least one annotated target (median correlation when sharing one target, 0.561 versus 0.297 when sharing zero targets; fig. S5, A and B) . Second, analysis of 50 different structural and therapeutic classes revealed that drugs belonging to the same class produced highly correlated behaviors in nearly all cases ( fig. S5C and fig. S6 ) (3) . For example, several structurally diverse selective serotonin reuptake inhibitors (SSRIs) similarly reduced waking, and sodium channel agonist insecticides induced large increases in waking activity ( fig. S5C and fig. S6 ). Third, behavioral profiling uncovered the polypharmacology of drugs with multiple targets. For example, the profile of the dopamine reuptake inhibitor and muscarinic acetylcholine receptor antagonist 3a-bis-(4-fluorophenyl) methoxytropane correlated only with drugs that also shared both properties, such as the anti-Parkinson's drug trihexyphenidyl ( fig. S7 ) (3) . Fourth, modulators of the major neurotransmitter pathways often induced locomotor and rest/wake effects in zebrafish larvae similar to those seen in mammals (figs. S8 to S15) (3). For example, a 2 -adrenergic receptor agonists (e.g., clonidine) were sedating, whereas b-adrenergic agonists (e.g., clenbuterol) were arousing, as in mammals ( fig. S8 ). These analyses indicate that compounds with shared biological targets yield similar and conserved phenotypes in our high-throughput behavioral profiling.
Detailed analyses revealed that the clustering of well-known and poorly characterized drugs could predict targets for compounds whose mode of action has been unclear (Fig. 3 ). For example, the pesticide amitraz coclustered with a 2 -adrenergic agonists (Fig. 3A) , consistent with reports that amitraz causes clonidine-like side effects in mammals and binds to a 2 -adrenergic receptors (9) . Similarly, sinapic acid methyl ether coclustered with N-methyl-D-aspartate (NMDA) receptor antagonists ( Fig. 3B ), which suggests that the mild anxiolytic effect of sinapic acid in mice is due to NMDA receptor antagonism rather than gaminobutyric acid (GABA) receptor activation, as proposed (10) . Indeed, several sinapic acid analogs are known to block NMDA-induced excitotoxicity in vitro (11, 12) . Finally, MRS-1220, an adenosine A3 receptor antagonist (13) , clustered with monoamine oxidase (MAO) inhibitor antidepressants (Fig. 3C ). To directly test whether MRS-1220 inhibits MAO, we performed an in vitro activity assay and found a median inhibitory concentration (IC 50 ) of~1 mM (Fig. 3D) . Thus, behavioral profiling in zebrafish larvae can predict and identify targets of poorly characterized compounds.
In addition to revealing a conserved neuropharmacology between zebrafish and mammalian rest/wake states (figs. S8 to S15) (3), behavioral profiling identified additional pathways involved in rest/wake behaviors: 1) L-type calcium channel inhibitors of the verapamil class increased rest with minimal effects on waking activity ( fig. S16 ). This is likely a direct effect on rest regulation, because average waking activity and associated muscle activity were unaffected.
2) Cluster analysis identified two structurally related podocarpatrien-3-ones that specifically increased rest latency (Fig. 4A ). These and other compounds also revealed that total rest, rest latency, and waking activity can be disassociated, indicating that these processes can be regulated by distinct mechanisms (3) .
3) Although inflammatory cytokine signaling has long been known to promote sleep during infection, a role for the immune system in normal vertebrate sleep/wake behavior has not been described (14) . Behavioral profiling revealed that a diverse set of anti-inflammatory compounds increased waking activity during the day with much less effect at night (Fig. 4B and  fig. S17 ). These anti-inflammatory compounds included the steroidal glucocorticoids, the nonsteroidal anti-inflammatory drugs (NSAIDs), phosphodiesterase (PDE) inhibitors, and other compounds with anti-inflammatory properties, including the immunosuppressant cyclosporine and the mood stabilizer valproic acid. Taken together, these data suggest that inflammatory signaling pathways not only induce sleep during infection (14) but also play a role in setting normal daytime activity levels.
4) Ether-a-go-go-related gene (ERG) potassium channel blockers selectively increased waking activity at night without affecting total rest ( Fig. 4C and fig. S18 ). This phenotype was induced by compounds with divergent therapeutic indications (e.g., the antimalarial halofantrine, the antipsychotic haloperidol, the antihistamine terfenadine); however, these drugs also inhibit the ERG channel and can cause the heart rhythm disorder long QT syndrome (15, 16) . Rank-sorting all the screened compounds by their fingerprints' mean correlation to the ERG-blocking cluster resulted in a significant enrichment of known ERG blockers in the top ranks (Fig. 4D) . Moreover, the specific ERG inhibitor dofetilide increased nighttime activity, whereas structurally related non-ERG blocking compounds, including the antihistamines fexofenadine and cetirizine, did not ( fig. S18B ). Finally, this phenotype was not caused by general misregulation of potassium channels, because psora-4, a drug that blocks the related shaker potassium channel Kv1.3, induced a distinct phenotype ( fig. S18A ). These results suggest that ERG potassium channels play a role in regulating wakefulness at night that is distinct Fig. 1 . Larval zebrafish locomotor activity assay. (A) At 4 days post-fertilization (dpf), an individual zebrafish larva is pipetted into each well of a 96-well plate with small molecules. Automated analysis software tracks the movement of each larva for 3 days. Each compound is tested on 10 larvae. (B) Locomotor activity of a representative larva. The rest and wake dynamics were recorded, including the number and duration of rest bouts [i.e., a continuous minute of inactivity (8) ], the timing of the first rest bout after a light transition (rest latency), the average waking activity (average activity excluding rest bouts), and the average total activity. Together, these measurements generate a behavioral fingerprint for each compound. from the role of shaker channels in regulating sleep in flies and mice (17, 18) .
As applied here, behavioral profiling reveals relationships between drugs and their targets, demonstrates a conserved vertebrate neuropharmacology, and identifies regulators of rest/wake states. Our findings have two major implications for the fields of neurobiology, pharmacology, and systems biology. First, behavioral profiling has the potential to complement traditional drug discovery methodologies by combining the physiological relevance of in vivo Fig. 2 . Hierarchical clustering reveals the diversity of drug-induced behaviors. (A) Behavioral profiles are hierarchically clustered to link compounds to behaviors. Each square of the clustergram represents the average relative value in standard deviations (yellow, higher than controls; blue, lower than controls) for a single behavioral measurement. Dark bars indicate specific clusters analyzed in subsequent figures. (B to F) Normalized waking activity and rest graphs are plotted for behavior-altering compounds (red trace; average of 10 larvae) and representative controls (10 blue traces; average of 10 larvae each). Compounds that altered behavior include the mood stabilizer and antiepileptic drug sodium valproate (B), the psychotomimetic NMDA antagonist L-701324 (C), the sodium channel agonist pesticide DDT (D), the antimalarial halofantrine (E), and the calcium channel blocker methoxyverapamil (F). assays with high-throughput, low-cost screening (3) . Future screens can be expanded to include many more uncharacterized compounds and to assay additional phenotypes, including those associated with human psychiatric disorders. In this way, behavioral profiling can characterize large classes of compounds and reveal differences in effectiveness, potential side effects, and combinatorial properties that might not be detected in vitro. Second, behavioral profiling allows for the systematic dissection of the pharmacology of complex behaviors. Our screen profiled the effects of dozens of neurotransmitter pathways and identified small molecules that regulate discrete aspects of rest/wake states. Future experiments can test drug combinations to identify synergistic or antagonistic effects among psychotropic compounds and to build interaction maps. High-throughput behavioral profiling thus may enable application of the logic and approaches of systems biology to neuropharmacology and behavior. H a l o f a n t r i n e 0 . 9 4 3 3 A m p e r o z i d e 0 . 9 2 9 5 T e r f e n a d i n e 0 . 9 1 8 7 C l o z a p i n e 0 . 9 1 3 8 P r o m e t h a z i n e 0 . in zebrafish offers a cost-effective way to characterize neuroactive drugs and to predict biological predicted by matching their behavioral profiles to those of well-known drugs. Thus, behavioral profiling regulate sleep. Moreover, the biological targets of poorly characterized small molecules can be conservation of zebrafish and mammalian sleep/wake pharmacology and identifies pathways that effects of thousands of drugs on sleep/wake behaviors of zebrafish larvae. The data set reveals a broad (p. 348) developed a high-throughput assay to assess the et al. Rihel direct testing in live animals.
The complexity of the brain makes it difficult to predict how a drug will affect behavior without
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Materials and Methods
Small molecule exposure. Larval zebrafish were raised on a 14 hour/10 hour light/dark cycle at 28. Locomotor activity analysis. The behavioral assay is adapted from (S1). Locomotor activity was monitored for 60 hours using an automated video tracking system (Videotrack; Viewpoint Life Sciences, Montreal, Quebec, Canada) with a Dinion onethird inch Monochrome camera (model LTC0385; Bosch, Fairpoint, NY) fitted with a fixed-angle megapixel lens (M5018-MP; Computar) and infrared filter. The movement of each larva was recorded using the Videotrack quantization mode, and data from two cameras were collected in alternating minutes by one computer. The 96-well plate and camera were housed inside a custom-modified Zebrabox (Viewpoint, LifeSciences) that was continuously illuminated with infrared lights and illuminated with white lights from 9 AM to 11 PM. The 96-well plate was housed in a chamber filled with circulating water to maintain a constant temperature of 28.5 o C. The Videotrack threshold parameters for detection used were: detection threshold, 40; burst, 25; freeze, 4; bin size, 60 seconds. Data analysis. The data was processed using custom PERL, Visual Basic Macros for Microsoft (Seattle, WA) Excel, and Matlab (version R2007a; The Mathworks, Inc). Any one minute bin with less than 0.1 second of total movement was defined as one minute of rest; a rest bout was defined as a continuous string of rest minutes (S1). Rest latency was defined as the length of time from lights on or off to the start of the first rest bout. Total activity was defined as the average amount of detected activity in seconds, including all rest bouts. Waking activity was defined as the total amount of detected activity, excluding all one minute periods of rest. These parameters were calculated for each experimental day and night, standardized to camera-matched DMSO controls, and expressed as +/-standard deviations from controls for hierarchical clustering (see below). We calculated the inter-assay variability as a coefficient of variation (standard deviation of all DMSO controls/mean of DMSO controls*100) for each measurement. For non-normal distributions, including rest length, rest latency, and wakingactivity, the coefficient of variation was calculated following a Box-Cox transformation to a normal distribution. The coefficient of variations (expressed as a %) are as follows: total rest, day 1, 42 To generate time series data for average rest per 10 minutes and average waking activity per 10 minutes (red traces, e.g. Figure 2B -F), these two parameters were averaged across all 10 replicate animals in 10 minute intervals and then normalized to camera matched controls by dividing each 10 minute rest and 10 minute waking activity measure by the mean daytime rest and activity for camera matched controls, respectively. For comparison, 10 representative sets of DMSO controls (10 larvae each set; e.g. blue traces in Figure 2B -F) are plotted in each time series. The same DMSO controls are shown in all graphs for clarity.
To identify compounds that significantly altered behavior, each parameter was compared to camera-matched DMSO controls by Student's t-test. Compounds were chosen for further analysis if either: 1) the compound altered the same parameter in the same direction at a p value < 10 -5 for two consecutive days or nights, 2) the compound affected a behavioral parameter at p<10 -10 within the first 24 experimental hours, or 3) the compound altered rest latency at p<0.001 for two consecutive days or nights but had little effect on other parameters. These parameters were chosen to select the largest manageable set of small molecules with the strongest and most consistent effects on behavior while minimizing false positives and compounds with spurious shortterm behavioral alterations. Biological targets were assigned to compounds based on annotations in the Pharmaprojects, Drugbank, Drugs@FDA, and Leadscope Marketed Drugs databases, as well as information supplied by the library vendors and detailed manual literature searches for each compound.
Hierarchical and k-means clustering analysis. Clustering analysis was performed with Cluster 3.0 (adapted by Michiel de Hoon from Cluster, written by Michael Eisen, (S2)) and visualized using TreeView (written by Michael Eisen, (S2) ). Hierarchical clustering was performed using Pearson uncentered correlation and average linkage. The parameters were weighted as follows: total rest, 1.0; rest bouts, 0.8; rest bout length 0.3, rest latency, 1.0; total activity and waking activity, 1.0. K-means clustering was performed using k=24 and Euclidean distance. To determine the relative position of the k-clusters, the average vector for each cluster was calculated, and these 24 vectors were hierarchically clustered using Euclidean distance.
Correlation Analysis: All correlation analysis was performed in Matlab (version R2007a; The Mathworks, Inc). The weighted, uncentered Pearson's correlation coefficients were calculated for all compound pairs. Compounds were assigned to pharmacological classes as described above. Compounds were considered to share targets if both their target assignment and activity (i.e. agonist or antagonist) overlapped for at least one target.
Rank Correlation Analysis: To perform rank correlation analysis for adrenergic antagonists and ERG blocking drugs, the average weighted uncentered Pearson's correlation coefficient between each compound of the identified cluster and every other small molecule was calculated. Each small molecule was then assigned a rank based on their mean correlation, with rank 1 being the highest mean correlation. Compounds that showed ERG or adrenergic antagonist activity were identified by their pharmacological assignments, and the Kolmogorov-Smirnov statistic was used to assign the p value for whether ERG or adrenergic antagonist compounds were enriched among the higher ranking compounds. The rank correlations were graphically represented in Treeview (S2). Dose Correlation Analysis. Compounds were ordered from Sigma-Aldrich (St. Louis, MO), dissolved in DMSO to a stock concentration of 30 or 45 mM and tested in the locomotor activity assay at final concentrations of 0. 15, 0.45, 1.5, 4.5, 15, and 45 µM, or 0.1, 0.3, 1.0, 10, and 30 µM (0.3% DMSO final concentration) . Each concentration was tested on 10-20 larvae. To generate the fingerprint for each concentration, the behavioral parameter measurements were standardized to camera-matched DMSO controls and expressed as +/-standard deviations from controls. Two-tailed t-test assessments (Bonferroni corrected for multiple comparisons) determined statistically significant differences of each measurement relative to camera-matched controls. The correlation matrices were generated by calculating the weighted, uncentered Pearson's correlation coefficient between the fingerprints for all concentration pairs. The fingerprint, significance, and correlation matrix heat maps were generated using Matlab (version R2007a; The Mathworks, Inc.).
MAO inhibitor assay. MAO-B activity was assayed as described (S3) .
Supplemental Texts 1-7
Supplemental Text 1. Psychotropic Drug Discovery The limitations of in vitro drug screening are particularly acute for the development of drugs that modulate the central nervous system (CNS). Surveys of drug discovery success show that CNS drugs take longer to develop (12.6 years versus 6.3 years for cardiovascular drugs) and fail to reach the market more often (7% success rate versus 15%) than other therapeutic indications (S4) . The CNS poses a particular challenge to drug discovery because the brain cannot be modeled in vitro. Indeed, most modern psychotropic drugs were first developed for non-psychotropic uses and serendipitously discovered to have behavior-altering side effects (e.g. the MAO inhibitor, iproniazid, was developed to treat tuberculosis and found to alter mood, and the tricyclic antidepressant imipramine was first used as an anti-histamine, (S5)). Furthermore, CNS drugs tend to produce undesirable side effects, including dizziness, tremors, lethargy, and seizures, which are difficult to predict at early stages of the drug discovery pipeline. Also, the mechanism of action for many CNS drugs, including bipolar medications, antidepressants, and antipsychotics, is poorly understood and in many cases may depend on a compound's complex poly-pharmacological actions across multiple neurotransmitter systems (S6-7) . Indeed, efforts to increase efficacy and reduce side effects through the development of newer generations of drugs with more selective target profiles has to date achieved only limited success (S8-9) .
Alternatives or complements to in vitro target-based screens include phenotype-based, whole organism screens. Such screens have several advantages. First, wholeorganism screens need not be limited to single, well-validated targets. In fact, whole organism screens can identify efficacious compounds with complex mechanisms of action. Second, unwanted side effects, an obstacle in any drug discovery pipeline, can be detected at earlier stages, even during the primary screening process. Third, compounds that produce a behavioral effect are bio-available, another major stumbling block to in vitro based drug discovery pipelines. In principle, whole organism phenotypic screening could replace serendipity, but the requirement for large numbers of phenotyped animals is usually cost and time prohibitive. Behavioral screening in zebrafish larvae offers a cost-effective model system for psychotropic drug characterization and discovery.
Supplemental Text 2. Dose
Choosing the compound concentration is a challenge for any large-scale small molecule screen. Effective doses can vary among compounds, but it is impractical in most cases to screen at multiple concentrations. The decision to perform our screen in the 10-30 µM range was based on the following considerations. First, we were guided by several previous studies. Developmental screens in zebrafish used concentrations of 10-50 µM (S10-12), single compound behavioral studies in zebrafish were done at 1-100 µM (S13-19) , and the connectivity map cell-based screen was performed at 10 µM (S20, 21) . Second, we performed a pilot screen of 96 compounds and found that only 10% of the compounds were overtly toxic at the 30 μM range, a percentage deemed acceptable for screening. Third, dose response curves on selected compounds indicated that a concentration of 10-30 µM was an effective range with consistent behavioral effects for most compounds (Table S1 and Fig. S4 ). Specifically, we found that fingerprints for the same compound were strongly correlated (25/29 cases) across the statistically effective concentration range (Fig. S4 ). These results show that the behavioral fingerprints are broadly stable across multiple doses.
Supplemental Text 3. Therapeutic Classes of Drugs Induce Correlated Behaviors
To test the potential of the clustering analysis, we determined whether compounds that share targets are more likely to produce similar phenotypes ( Fig. S5A-B) . Expanding this correlation analysis to 50 categories of drugs, we found, with few exceptions, that the correlations among related classes of compounds were much larger than chance (Fig. S5C) . In many cases, every intra-class pair-wise correlation was larger than the zero target correlation (see Figure Many compounds have multiple, potentially non-overlapping targets. In such cases, one would expect that not all compounds that share targets produce similar phenotypes ( Fig. S5A-C ). For example, outliers of the correlation analysis might reflect the difficulty in assigning compounds to single classes when in fact they have multiple targets. This observation can be used to identify potential polypharmacological effects (Figs. S5C and S7) . For example, NMDA antagonist (NMDA-) outliers included compounds that also bind to σ-opioid receptors (e.g. 3-methoxymorphinan), the GABA antagonist (GABA-) outlier tert-butyl-bicyclophosphorothionate (TBPS) also potently blocks chloride channels, the serotonin receptor 1A antagonist (5HT-1A-) outlier S(-)UH-301 is also a dopamine D2/3 receptor agonist, and the dopamine D2 receptor agonist (DOPA-D2+) outlier pergolide is also a serotonin receptor agonist ( Fig S5C) . Our correlation analysis can also uncover higher order associations among drugs with multiple targets, such as the high correlation between drugs that share dopamine reuptake inhibition and acetylcholine antagonism ( Figure S7A-B) . Furthermore, the clustering analysis can reveal unexpected associations between annotated drug classes. For example, a cluster of known α1-adrenergic receptor antagonists (ifenprodil, terazosin, and 5-methylurapidil) also cluster with several serotonin receptor modulators, including NAN-190, RU-24969, WAY-100635, spirotraxine, and buspirone ( Fig. S7C-D) . Intriguingly, buspirone and spirotraxine do not strongly bind to α1-adrenergic receptors in vitro yet can show in vivo adrenergic activity in specific pharmacological contexts (22). These results show that behavioral profiling can uncover associations between multi-target drugs whose properties are not fully predicted by in vitro studies.
Supplemental Text 5. Pharmacological Conservation (Figs. S8-15).
We systematically compared the behavioral effects of agonists and antagonists of the major neurotransmitter systems between zebrafish and mammals. In most cases, confidence in the conservation between zebrafish and mammals is enhanced when multiple compounds known to affect the same target elicit similar phenotypes and when agonist/antagonist pairs elicit opposing phenotypes. We discuss each class in more detail below.
Adrenaline (Fig. S8 ). In zebrafish, α2-adrenergic agonists decreased wakefulness with little effect on rest, while activation of β-adrenergic receptors selectively reduced total rest at night. Conversely, β-adrenergic receptor antagonists increased total rest. α1-adrenergic antagonists gave a "mixed" phenotype of increased waking activity but also increased rest. These effects are broadly consistent with those observed in mammals (S23-35).
Serotonin (Fig. S9 ). The analysis of serotonin-regulating drugs is complicated because most, if not all, serotonin-modulating drugs have considerable affinity for non-serotonin receptors, especially dopaminergic and adrenergic receptors. Thus, the drugs chosen for the table in Figure S9 combine serotonin-signaling selectivity, consistency of phenotype, and reproducibility (i.e. multiple hits within the screen of the same or similar compounds). As often as possible, the drugs shown have known mammalian phenotypes (S36-55) . The complexity of the phenotypes we observed with serotonergic agonists and antagonists is similar to the controversial and contradictory nature of the mammalian literature pertaining to these drugs. This may reflect the difficulty in isolating the drugs' effects on serotonin signaling from other secondary effects, differences between short-term and long-term exposure, or complex signaling interactions among different populations of serotonergic neurons in the brain. For example, in mammals agonists and antagonists of serotonin receptor 1A both cause short-term reduction of sleep and increase in wakefulness followed by longer-term increases in sleep and reduced activity (S36-40, S45-47) . In long-term experiments, both classes of drugs increased rest in zebrafish. Only buspirone had an observed short-term increase in waking during the first night of the experiment (black arrow in Fig.  S9 ). Serotonin receptor 2/3 antagonists have paradoxical effects in mammals, increasing both exploratory behavior and sleep (S38, S44, S49-52) . Similarly, both waking activity and total rest were increased in zebrafish. Finally, SSRIs consistently decreased waking activity and increased rest in zebrafish; in human patients, SSRIs often improve insomnia in depressed patients but can have biphasic effects on sleep, with long-term decreases in sleep in some mammalian models (S53-55). Dopamine ( Fig. S10 ). With one notable exception, dopamine receptor agonists and antagonists produce similar phenotypes in mammals and zebrafish (S56-67) . For example, the D2-receptor agonists consistently reduced waking activity and increased rest in zebrafish, as they do at low concentrations in mammals (S60-63) . This effect was receptor subtype selective, as the D2/D3 receptor agonists quinelorane and quinpirole only reduced waking activity (S64, S65) . As another example of conservation, D2-receptor antagonists, several of which are used as anti-psychotics, increase waking activity and rest in zebrafish and mammals (S57, S62, S67) . Previous work indicated that antipsychotics produce locomotor defects in zebrafish larvae (S15-16) . The only clear examples of non-conserved pharmacology in our study were the dopamine D1 agonists (Fig. S10 , marked in gray), all of which had little effect on waking activity but greatly increased total rest in zebrafish. In all mammalian species tested, dopamine D1 agonists increased waking (S56-59) . This could indicate a distinct role for the zebrafish orthologs of D1 receptors in the control of behavior or that these dopamine D1 agonist drugs have altered target selectivity in zebrafish.
GABA (Fig. S11 ). While many of the GABA-regulating benzodiazepine drugs were toxic at the concentrations used in our screen, the GABA-A agonists GBLD-345 and avermectin B1 increased total rest and had only a small effect on waking activity (S68). Although only represented by a single hit in the screen, the GABA-B agonist CGP-13501 ( Fig. S11 , marked in gray) slightly increased waking activity at night with very modest increases in rest during the day, even though this drug is hypnotic in mammals (S69). In contrast, many GABA-A antagonists dramatically increased waking activity, possibly reflecting pro-convulsant effects of these drugs on zebrafish larvae, which is consistent with the mammalian literature (S70-72) and with previous work in zebrafish (S13, S17, S19) . Tracazolate, an anxiolytic acting as an allosteric modulator of GABA-A receptors, modestly increased waking activity in zebrafish; in mammals, tracazolate can both increase or decrease locomotor activity (S73, S74) . Intriguingly, the neuroactive steroid GABA agonists allopregnanolone, pregnanolone, and alfadolone increased both total rest and waking activity specifically at night (S75-77). As neuroactive steroids have additional functions in mammalian brains, including modulation of NMDA receptors (S75), this mixed phenotype may reflect the polypharmacology of these compounds.
Melatonin (Fig. S12 ). Although only a few examples were present in our screen, melatonin-modulating drugs gave results that are consistent with those observed in mammals (S78-82) and previous work in zebrafish (S14) . Melatonin slightly increased rest in our long-term experiments. In addition, the melatonin agonist 8-methoxy-1-propionamidotetralin decreased waking activity and increased rest. An exception was the agonist IIK7 (S78), which slightly increased waking activity at night and had small effects on rest.
Histamine (Fig. S13 ). Histamine antagonists identified in our screen tended to increase rest, decrease waking activity, or both. This increased rest in zebrafish is consistent with the mammalian literature, although it should be noted that anti-histamine drugs that do not cross the blood-brain barrier in humans, such as loratadine, tend to be less sedating than the older generation of drugs that do cross the blood-brain barrier (S83-87) . Our work is also consistent with previous work on anti-histamines in zebrafish larvae (S13, S18) . Notably, the anti-histamine diphenylpyraline increased waking activity, consistent with reports of psychostimulatory effects in rodents (S87) . Also, as noted in the main text and Figures 4C-D and S18, anti-histamines that block the human ether-a-go-go related potassium channel (ERG) consistently increased waking activity at night, with modest effects on rest in zebrafish larvae.
Adenosine (Fig. S14) . Consistent with mammals, adenosine receptor agonists increased rest in zebrafish larvae, while adenosine receptor A1 antagonists increased waking activity and reduced rest (S88-93) . Although behavioral effects of the adenosine A3 antagonist MRS-1220 are unknown in mammals, it decreased waking activity and increased rest in zebrafish. This phenotype is consistent with its inhibitory effects on MAO ( Figure 3D ).
Glutamate (Fig. S15 ). All NMDA receptor antagonists identified in the screen dramatically increased waking activity during the day and night, consistent with the effects observed in mammals (S94, S95) . Muscarinic glutamate receptor 5 (mGluR5) antagonists selectively increased rest, with little effect on waking activity. Antagonists of mGluR5 can block drug-induced hyperlocomotion, down-regulate bursting of prefrontal cortical neurons in awake rats, and have anxiolytic properties in rodents (S96, S97) .
Supplemental Text 6. Non-overlapping Regulation of Rest/Wake States. Many pharmacological agents selectively altered waking activity, rest latency, or total rest. For example, verapamil related L-type calcium channel inhibitors increased rest with no effect on waking activity (Fig. S16) , while β-adrenergic agonists, including clenbuterol and fenoterol, decreased rest only (Fig. S8 ). Non-competitive NMDA receptor antagonists, including the psychotomimetics dizocilpine (MK-801) and L-701324, predominantly increased waking activity with minimal effects on total rest (Figs. 2C and S15), the D2/D3 agonist, ropinirole, predominantly decreased waking activity only (Fig. S10) , and podocarpatrien-3-one analogs predominantly altered only rest latency (Fig. 4A ). These single parameter effects can also be selective for day versus night. For example, many anti-inflammatory compounds only increased waking activity during the day (Figs. 2B, 4B and S17), while ERG-blocking drugs increased waking activity at night (Figs. 2E, 4C-D, S18). Finally, some compounds can affect waking activity and total rest in opposite directions (e.g. increase both waking activity and total rest). For example, the α1-adrenergic antagonists ifenprodil, the antimalarial quinacrine, and the steroidal GABA agonist alfadolone, increased both waking activity and total rest (Figs S7C, S11). These observations suggest that the behavioral parameters of waking activity, total rest, and rest latency during the day and the night can be under the control of distinct pharmacological mechanisms.
Supplemental Text 7. High Throughput Behavioral Screening in Practice
Behavioral profiling in zebrafish is highly efficient. Our current zebrafish behavior room (~200 sq. ft.) has 16 cameras that can each observe 80 wells of a 96-well plate, for a total of 1280 larvae. Using our original screening method of 10 larvae per compound and including 10 control wells for each camera, we can screen 112 compounds (16 cameras x 7 drugs per camera) every three days, or 224 compounds per week. Using the latest videotracking software, which can track all 96 wells of the plate, and cutting the number of larvae per drug to eight expands our capacity to 352 compounds per week (16 cameras X 11 drugs per camera X 2 runs per week). A single technician can set up the entire behavioral room in less than 4 hours, including fish husbandry, larval pipetting, drug dispensing, and software setup (an 8 hour commitment per week). Expanding the screen to 115 cameras and 5 technicians (a total commitment of 40 hours per week) would increase the throughput to more than 10,000 compounds per month and more than 100,000 per year. Figure S1 . Expanded hierarchical clustering analysis. This is an expanded version of Figure 2A in which the name of each chemical in the clustergram can be seen. Each row represents a different chemical, and each column represents a behavioral measurement. From left to right, these measurements are: the rest total, the number of rest bouts, the rest bout length, the rest latency, the total activity, and the waking activity. The black bars indicate night measurements; the white bars indicate day measurements. Yellow indicates that the value is increased relative to controls; blue indicates that the value is decreased, as in Figure 2A . The measurements are normalized as standard deviations from control values. Figure S2 . Hierarchical and k-means clustering yield similar cluster architectures. Each row represents a different chemical, and each column represents a behavioral measurement. From left to right, these measurements are: the rest total, the number of rest bouts, the rest bout length, the rest latency, the total activity, and the waking activity. The black bars indicate night measurements; the white bars indicate day measurements. Yellow indicates that the value is increased relative to controls; blue indicates that the value is decreased, as in Figure 2A . The measurements are normalized as standard deviations from control values. Figure S3 . Expanded k-means clustergram. This is an expanded version of Figure S2 in which the name of each chemical in the clustergram can be seen. Each row represents a different chemical, and each column represents a behavioral measurement. From left to right, these measurements are: the rest total, the number of rest bouts, the rest bout length, the rest latency, the total activity, and the waking activity. The black bars indicate night measurements; the white bars indicate day measurements. Yellow indicates that the value is increased relative to controls; blue indicates that the value is decreased, as in Figure 2A . The measurements are normalized as standard deviations from control values. Figure S4 . Behavioral fingerprints are stable across a range of doses. Select compounds were tested for behavioral effects at multiple concentrations (see Table S1 for additional examples and summary data). First, the fingerprints for each dose were calculated as standard deviations from DMSO controls ('Fingerprint', left panels). In general, these fingerprints are stable across multiple concentrations until the dose is too low to elicit a phenotype. To assess the stability of single drug fingerprints over multiple concentrations, the Pearson uncentered correlation coefficient was calculated pairwise between each dose ('correlation matrix', right panels). With the exception of pergolide and several other ergoline derivatives, which have distinct fingerprints at high versus low concentrations, these examples have relatively stable fingerprints from the highest dose tested (45 μM) to the lowest effective doses (150 nM for NAN-190 and betamethasone, 450 nM for ropinirole, 1.5 µM for clonidine and buspirone), as indicated by the high correlations (red boxes). See Materials and Methods for additional information. ; α-adrenergic receptor-2, ADR-A2; β-adrenergic, ADR-B; noradrenaline reuptake inhibitor, ADR-U-; serotonin/noradrenaline reuptake inhibitor, SNRI; selective serotonin reuptake inhibitor, SSRI; serotonin receptor-1A, 5HT-1A; serotonin receptor-1D, 5HT-1D; serotonin receptor-2, 5HT-2; serotonin receptor-2/3, 5HT-2/3; serotonin receptor 4, 5HT-4; monoamine oxidase inhibitor, MAO-; neurotransmitter inhibitor (reserpine class), NEURO-; dopamine receptor, DOPA; dopamine D1 receptor, DOPA-D1; dopamine D2 receptor, DOPA-D2; dopamine D2/3 receptor, DOPA-D2/3; dopamine D3 receptor, DOPA-D3; dopamine D4 receptor, DOPA-D4; γ-butyric acid receptor, GABA; histamine H1 receptor, HIST-H1; ether-a-go-go-related potassium channel, ERG; adenosine signaling, ADS; metabotropic glutamate receptor 5, mGLUR5; N-methyl-D-aspartic acid receptor, NMDA; acetylcholinesterase inhibitor, ACH-ES-IRev, irreversible; Rev, reversible; muscarinic acetylcholine receptor; ACH-M; nicotinic acetylcholine receptor, ACH-N; acetylcholine synthesis, ACH-SY; L-type calcium channel; CHA-CA-L; sodium channel, CHA-NA; peroxisome proliferator-activated receptor, alpha, PPAR-A. Figure S6 . Examples of compounds that share biological targets and/or structural similarity that give similar behavioral profiles. (A) Structurally divergent selective serotonin reuptake inhibitors (SSRIs) similarly decrease waking activity and increase rest. (B) Structurally related insecticides dramatically increase waking activity independent of the time of day. The graphs represent the normalized waking activity and total rest for behavior-altering compounds (red trace; average of 10 larvae) and representative controls (10 blue traces; average of 10 larvae each). shown for two ERG-blocking compounds (red trace = average of 10 larvae) and representative controls (10 blue traces = average of 10 larvae). Both compounds increased waking activity at night without affecting rest. Psora-4, which blocks Kv1.3 shaker channels, increased nighttime waking activity and also strongly decreased rest, a phenotype distinct from ERG blockers. Thus, the ERG phenotype is not the result of general potassium channel misregulation. (B) Dose response curves for ERG blocking and ERG non-blocking analogs are shown. Each point indicates the waking activity at night (seconds per minute) averaged for 10 larvae. Cisapride and dofetilide, which have ERG blocking activity, dose-dependently increased nighttime wakefulness, while the non-ERG blocking histamine H1 receptor antagonists fexofenadine and cetirizine had no effect on wakefulness. Another non-ERG blocking anti-histamine, loratadine, reduced waking activity. Error bars represent +/-SEM. The 0 M concentration is a DMSO control. 11, 11, 
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